FDA
FDA Articles
Analysts are beginning to flock to Sarepta after the company made news surrounding a meeting with the FDA, not to mention the enormous boost that shares are getting from short covering.
Published:
Pain Therapeutics has announced top-line results for an FDA Category 3 Human Abuse Potential Study with Remoxy Extended-Release Capsules CII.
Published:
Array BioPharma released disappointing fiscal third-quarter earnings before the markets opened Monday morning.
Published:
ThinkstockThe trend towards generic drugs is nothing new. It does not matter if a drug has billions of dollars in annual sales or not, when they go off patent generics can enter the market. Now the...
Published:
Celladon announced negative results in clinical trial and shares plunged 80% Monday morning.
Published:
A late day call on Thursday from Bank of America Merrill Lynch took GW Pharmaceuticals' share price target far higher.
Published:
Bird flu is making its way back into the news, and the fears of it spreading are carrying over into any companies with exposure to chickens, turkeys and the like.
Published:
The most recent analyst call by Merrill Lynch for BioCryst Pharmaceuticals may be very misunderstood for what it is.
Published:
Last Updated:
Ampio announced Monday that a Phase 3 for the treatment pain due to osteoarthritis of the knee did not reach its primary endpoint against a saline control.
Published:
A recent Quinnipiac University Swing State Poll shows that voters in the swing states of Florida, Ohio and Pennsylvania now support legalization of marijuana use.
Published:
So far, analysts have not backed off their bullish views of Dyax. In fact, many analysts boosted their price targets remarkably on the news.
Published:
Dyax is almost certain to dominate the biotech news flow on Wednesday, after it announced positive trial data on Tuesday evening.
Published:
AcelRx Pharmaceuticals announced an update on the timing and potential content of its resubmission of the New Drug Application (NDA) for Zalviso.
Published:
ThinkstockOncolytics Biotech Inc. (NASDAQ: ONCY) announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug designation for Reolysin. Reolysin is the company’s lead product...
Published:
Last Updated:
Sarepta Therapeutics received a favorable rating from Merrill Lynch, and as a result the stock soared in Tuesday's trading session.
Published:
Last Updated: